Clinical trial · Observational
Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection
NCT06970288CI-TRIAL-00089631recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the capability of detecting suspicious breast lesions using non-contrast enhanced MRI protocol featuring ultra-high B-value
- timeFrame
- 20 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * • Women with suspicious breast mass (BIRADS 4a) * High risk women (Positive family history) * Women with suspicious axillary lymph nodes by Ultrasound * Women with dense breasts coming for MRI imaging. Exclusion Criteria: * • Contraindications to MRI * Pacemaker, cochlear implant, claustrophobia, ocular implants * Contraindications to contrast administration: * Elevated kidney functions * Women who haven't undergone reliable Mammogram \& Ultrasound * Women with prior treatment or intervention (e.g. biopsy) * Patients' refusal.
References
Publications (0)
Data not yet available
No reference posted for this study.